$214 Million is the total value of DAFNA Capital Management LLC's 75 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STXS | STEREOTAXIS INC | $10,534,000 | +15.8% | 13,680,554 | 0.0% | 4.93% | +11.5% | |
| NXTM | NXSTAGE MEDICAL INC | $8,541,000 | +12.2% | 306,119 | 0.0% | 4.00% | +8.0% | |
| ALDR | ALDER BIOPHARMACEUTICALS INC | $6,257,000 | +24.4% | 396,013 | 0.0% | 2.93% | +19.7% | |
| AKBA | AKEBIA THERAPEUTICS INC | $6,095,000 | +4.7% | 610,738 | 0.0% | 2.85% | +0.8% | |
| RADIUS HEALTH INCnote 3.000% 9/0 | $3,725,000 | -6.9% | 4,000,000 | 0.0% | 1.74% | -10.4% | ||
| IBB | ISHARES TR NASDAQ BIOTECHetf | $2,866,000 | +2.9% | 26,100 | 0.0% | 1.34% | -1.0% | |
| PROTALIX BIOTHERAPEUTICS INCnote 4.500% 9/1 | $2,375,000 | +11.8% | 2,500,000 | 0.0% | 1.11% | +7.5% | ||
| INSULET CORPnote 1.375% | $1,664,000 | -2.7% | 1,500,000 | 0.0% | 0.78% | -6.4% | ||
| AGTC | APPLIED GENETIC TECHNOL CORP | $1,558,000 | -3.9% | 421,000 | 0.0% | 0.73% | -7.6% | |
| IMDZ | IMMUNE DESIGN CORP | $1,495,000 | +37.9% | 328,500 | 0.0% | 0.70% | +32.8% | |
| NTUS | NATUS MEDICAL INC | $1,308,000 | +2.6% | 37,900 | 0.0% | 0.61% | -1.3% | |
| JNJ | JOHNSON AND JOHNSON | $1,141,000 | -5.3% | 9,400 | 0.0% | 0.53% | -8.9% | |
| ADXS | ADVAXIS INC | $1,011,000 | -14.2% | 697,000 | 0.0% | 0.47% | -17.5% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $792,000 | -22.0% | 373,702 | 0.0% | 0.37% | -24.9% | |
| MASI | MASIMO CORPORATION | $488,000 | +10.9% | 5,000 | 0.0% | 0.23% | +6.5% | |
| BTX | BIOTIME INC | $374,000 | -23.5% | 181,600 | 0.0% | 0.18% | -26.5% | |
| SLGL | SOL GEL TECHNOLOGIES LTD | $270,000 | -25.2% | 35,000 | 0.0% | 0.13% | -28.4% | |
| ALDER BIOPHARMACEUTICALS INCnote 2.500% 2/0 | $261,000 | +15.0% | 250,000 | 0.0% | 0.12% | +10.9% | ||
| NEOS | NEOS THERAPEUTICS INC | $172,000 | -24.6% | 27,500 | 0.0% | 0.08% | -27.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.